Evidence map›Paper›PMID 37864578›Full record

ArticleEuropean heart journal2023

Ertugliflozin and hospitalization for heart failure across the spectrum of pre-trial ejection fraction: post-hoc analyses of the VERTIS CV trial.

Ambarish Pandey, Ahmed A Kolkailah, Francesco Cosentino, Christopher P Cannon, Robert C Frederich, David Z I Cherney, Samuel Dagogo-Jack, Richard E Pratley, Nilo B Cater, Ira Gantz and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European heart journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Trial
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Ambarish PandeyDivision of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390-9047, USA.ORCID 0000-0001-9651-3836
Ahmed A KolkailahDivision of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390-9047, USA.ORCID 0000-0002-3327-1718
Francesco CosentinoUnit of Cardiology, Department of Medicine, Karolinska Institute and Karolinska University Hospital, Stockholm, Sweden.ORCID 0000-0002-6967-5685
Christopher P CannonCardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0003-4596-2791
Robert C FrederichPfizer Inc, Groton, CT, USA.ORCID 0000-0002-5175-3112
David Z I CherneyDivision of Nephrology, University Health Network, University of Toronto, Toronto, ON, Canada.ORCID 0000-0003-4164-0429
Samuel Dagogo-JackUniversity of Tennessee Health Science Center, Memphis, TN, USA.ORCID 0000-0001-5318-9677
Richard E PratleyAdventHealth Translational Research Institute, Orlando, FL, USA.ORCID 0000-0002-2912-1389
Nilo B CaterPfizer Inc, New York, NY, USA.ORCID 0000-0001-5868-8643
Ira GantzMerck & Co., Inc, Rahway, NJ, USA.
James P MancusoPfizer Inc, Groton, CT, USA.
Darren K McGuireDivision of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390-9047, USA.ORCID 0000-0002-6412-7989

Funding

Merck & Co., Inc.Merck Sharp & Dohme LLCPfizer Inc
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Diabetes Mellitus, Type 2Heart FailureBridged Bicyclo Compounds, HeterocyclicHospitalizationHumansStroke VolumeBridged Bicyclo Compounds, Heterocyclicertugliflozin

Identifiers

PMID37864578
PMCPMC10733716

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.